Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CellSource Co's Enterprise Value is 円24,847 Mil.
CellSource Co's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was 円1,114 Mil. Therefore, CellSource Co's EV-to-EBIT ratio for today is 22.31.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, CellSource Co's Enterprise Value is 円24,847 Mil.
CellSource Co's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was 円1,114 Mil. Therefore, CellSource Co's EV-to-EBITDA ratio for today is 22.31.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, CellSource Co's Enterprise Value is 円24,847 Mil.
CellSource Co's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was 円4,625 Mil. Therefore, CellSource Co's EV-to-Revenue ratio for today is 5.37.
CellSource Co Enterprise Value Historical Data
The historical data trend for CellSource Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CellSource Co's Enterprise Value
For the Biotechnology subindustry, CellSource Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where CellSource Co's Enterprise Value falls into.
CellSource Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
CellSource Co's Enterprise Value for the fiscal year that ended in Oct. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
CellSource Co's current Enterprise Value is 円24,847 Mil.
CellSource Co's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,114 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
CellSource Co's current Enterprise Value is 円24,847 Mil.
CellSource Co's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,114 Mil.
CellSource Co's current Enterprise Value is 円24,847 Mil.
CellSource Co's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,625 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of CellSource Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4880 has been successfully added to your 